Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Cash from Operations: 2016-2024

Historic Cash from Operations for Solid Biosciences (SLDB) over the last 9 years, with Dec 2024 value amounting to -$100.0 million.

  • Solid Biosciences' Cash from Operations fell 42.37% to -$29.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$100.0 million, marking a year-over-year decrease of 6.19%. This contributed to the annual value of -$100.0 million for FY2024, which is 6.19% down from last year.
  • Per Solid Biosciences' latest filing, its Cash from Operations stood at -$100.0 million for FY2024, which was down 6.19% from -$94.2 million recorded in FY2023.
  • In the past 5 years, Solid Biosciences' Cash from Operations registered a high of -$56.6 million during FY2020, and its lowest value of -$100.0 million during FY2024.
  • Moreover, its 3-year median value for Cash from Operations was -$98.0 million (2022), whereas its average is -$97.4 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first spiked by 38.95% in 2020, then tumbled by 37.39% in 2021.
  • Yearly analysis of 5 years shows Solid Biosciences' Cash from Operations stood at -$56.6 million in 2020, then crashed by 37.39% to -$77.8 million in 2021, then fell by 25.99% to -$98.0 million in 2022, then rose by 3.88% to -$94.2 million in 2023, then dropped by 6.19% to -$100.0 million in 2024.